BCM
ALXN

Blume Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Blume Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-55
Closed -$10K – 289
2015
Q1 		$10K Hold
55
– – 0.01% 229
2014
Q4 		$10K Buy
+55
New +$10.2K 0.01% 243

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Blume Capital Management's ALXN Position: Q2 2015 in Review

Blume Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2015, closing a stake of 55 shares — an estimated $10K sold.

Blume Capital Management first reported a position in ALXN in Q4 2014 and held it in 2 quarters. The position peaked at $10K in Q1 2015. 547 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

  • Blume Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Blume Capital Management sold 55 Alexion Pharmaceuticals shares in Q2 2015, an estimated $10K.
  • Blume Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Blume Capital Management's Alexion Pharmaceuticals position peaked at $10K in Q1 2015.
  • 547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on Blume Capital Management's 13F filing for Q2 2015, filed 11 Aug 2015.